Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Cancer Immunology, Immunotherapy : CII|December 7, 2019
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancerYuki Ozaki, Satoshi Muto, Hironori Takagi, et al.
Trials|October 20, 2017
The efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trialTakuya Inoue, Hironori Takagi, Yuki Owada, et al.
Oncology Letters|June 11, 2017
Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeonsMitsunori Higuchi, Hironori Takagi, Yuki Owada, et al.
Biomedicines|January 21, 2023
Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other CancersSatoshi Muto, Akio Enta, Yoshiyuki Maruya, et al.
Oncology Letters|February 12, 2021
Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burdenSatoshi Muto, Yuki Ozaki, Hikaru Yamaguchi, et al.
Oncology Letters|February 14, 2018
Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptorTakumi Yamaura, Junji Ezaki, Naoyuki Okabe, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2021
Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004)Hironori Takagi, Songji Zhao, Satoshi Muto, et al.
Pageof 4